CCCC — C4 Therapeutics, Inc.
CIK 1662579 · SEC EDGAR fundamentals
Latest 10-K filed February 26, 2026 · period ending December 31, 2024
Headline figures
Top-line sales for the most-recent fiscal year
FY2025 · 10-K
Profit after all expenses, taxes, interest
FY2025 · 10-K
Net income per diluted share outstanding
FY2025 · 10-K
Cash actually generated by the business
FY2025 · 10-K
Balance sheet
Everything the company owns
FY2025 · 10-K
Everything the company owes
FY2025 · 10-K
Assets minus liabilities (book value)
FY2025 · 10-K
Debt due more than 12 months out
FY2023 · 10-K
Revenue history
Revenue from Contract with Customer, Excluding Assessed Tax · FY values from RevenueFromContractWithCustomerExcludingAssessedTax
| Fiscal year | Revenue | vs prior | Source |
|---|---|---|---|
| FY2025 | $35.6M | +71.4% | 10-K |
| FY2024 | $20.8M | -33.3% | 10-K |
| FY2023 | $31.1M | -32.1% | 10-K |
| FY2022 | $45.8M | — | 10-K |
Read the source
All figures on this page were filed by C4 Therapeutics, Inc. with the SEC and pulled directly from EDGAR's XBRL CompanyFacts API. Click below to view the latest annual report (10-K) in full.
Open latest 10-K on SEC EDGAR →📈 Our take on CCCC
Read the TradesZ deep dive — thesis, catalysts and risks.
Data sources & methodology
- SEC EDGAR — official company filings (full-text search) ↗
- SEC EDGAR — institutional Form 13F holdings ↗
- U.S. House Clerk — Periodic Transaction Reports (Congress) ↗
All figures derive from official, public-domain government filings. Read our methodology for how we collect, process and score this data. See the methodology →
TZ Researched & published by TradesZ Research
Not investment advice. Figures sourced from the SEC's XBRL CompanyFacts API — public-domain federal records. Companies occasionally restate prior-year numbers; we show the latest filed value per fiscal year.